• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    GoodRx Reports First Quarter 2025 Results

    5/7/25 4:13:00 PM ET
    $GDRX
    EDP Services
    Technology
    Get the next $GDRX alert in real time by email

    First Quarter 2025 Revenue In-line; Adjusted EBITDA Margin Beats Previous Guidance; Maintains Full Year 2025 Revenue Guidance Range; Raises Adjusted EBITDA Expectations

    GoodRx Holdings, Inc. (NASDAQ:GDRX) ("we," "us," "our," "GoodRx," or the "Company"), the leading platform for medication savings in the U.S., has released its financial results for the first quarter of 2025.

    First Quarter 2025 Highlights

    • Revenue of $203.0 million
    • Net income of $11.1 million; Net income margin of 5.4%
    • Adjusted Net Income1 of $34.4 million; Adjusted Net Income Margin1 of 16.9%
    • Adjusted EBITDA1 of $69.8 million; Adjusted EBITDA Margin1 of 34.4%
    • Net cash provided by operating activities of $9.4 million
    • Exited the quarter with over 7 million consumers of prescription-related offerings2

    "Since stepping into this role, I have dedicated my time strengthening our leadership team, gaining a deeper understanding of our business, meeting with key partners, understanding the macroeconomic environment, and identifying key capabilities and growth opportunities," said Wendy Barnes, Chief Executive Officer and President of GoodRx. "I can confidently say that we are in a very strong position to deliver meaningful value across the pharmacy ecosystem. Furthermore, we are focused on high-impact initiatives that we believe will drive our business forward in compelling ways."

    1

    Adjusted EBITDA, Adjusted EBITDA Margin, Adjusted Net Income, and Adjusted Net Income Margin are non-GAAP financial measures and are presented for supplemental informational purposes only. Adjusted EBITDA Margin and Adjusted Net Income Margin are defined as Adjusted EBITDA and Adjusted Net Income, respectively, divided by Adjusted Revenue. Refer to the Non-GAAP Financial Measures section below for definitions, additional information, and reconciliations to the most directly comparable GAAP measures.

    2

    Sum of Monthly Active Consumers (MACs) for Q1'25 and subscribers to our subscription plans as of March 31, 2025. Refer to Key Operating Metrics below for definitions of Monthly Active Consumers and subscription plans.

    First Quarter 2025 Financial Overview (all comparisons are made to the same period of the prior year unless otherwise noted):

    Revenue increased 3% to $203.0 million compared to $197.9 million.

    Prescription transactions revenue increased 2% to $148.9 million compared to $145.4 million, primarily driven by improved unit economics related to contracting with our customers and partners and sales mix, partially offset by a 4% decrease in Monthly Active Consumers, primarily due to the broader changes in the retail pharmacy landscape.

    Subscription revenue decreased 7% to $21.0 million compared to $22.6 million, primarily driven by a decrease in the number of subscription plans principally due to the sunset of our partnership subscription program, Kroger Savings Club.

    Pharma manufacturer solutions revenue increased 17% to $28.6 million compared to $24.5 million, driven by organic growth as we continued to expand our market penetration with pharma manufacturers and other customers, including ongoing growth in our point of sale discount programs.

    Net income was $11.1 million compared to a net loss of $1.0 million. Net income margin was 5.4% compared to a net loss margin of 0.5%. Adjusted Net Income1 was $34.4 million compared to $32.6 million.

    Adjusted EBITDA1 was $69.8 million compared to $62.8 million. Adjusted EBITDA Margin1 was 34.4% compared to 31.7%.

    Cash Flow and Capital Allocation

    Net cash provided by operating activities in the first quarter was $9.4 million compared to $42.6 million in the comparable period last year driven by changes in operating assets and liabilities, partially offset by an increase in net income after adjusting for non-cash items. Changes in operating assets and liabilities were principally driven by the timing of payments of prepaid services, accounts payable and accrued expenses, income tax payments and refunds, as well as collections of accounts receivable. As of March 31, 2025, we had cash and cash equivalents of $301.0 million and total outstanding debt of $498.8 million.

    We are focused on a disciplined approach to capital allocation, centered on furthering our mission and creating shareholder value. Our capital allocation priorities are investing for profitable growth, paying down debt, buying back shares, and M&A that aligns with our strategic priorities. These capital allocation priorities support our long-term growth strategy while also providing flexibility to navigate near-term challenges.

    Share Repurchases

    During the first quarter of 2025, we repurchased 23.3 million shares of Class A common stock for an aggregate of $100.9 million. As of March 31, 2025, we had $189.4 million of unused authorized share repurchase capacity under our $450.0 million share repurchase program, which does not have an expiration date.

    Guidance

    For the full year 2025, management is anticipating the following:

    $ in millions

    FY 2025

    FY 2024

    YoY Change

    Revenue

    $810 - $840

    $792.3

    2% - 6%

    Adjusted EBITDA3

    $273 - $287

    $260.2

    5% - 10%

    "For the full year 2025, we continue to believe that revenue will be in the range of $810 to $840 million, representing 2% to 6% growth compared to 2024," said Chris McGinnis, Chief Financial Officer and Treasurer. "There are a number of factors that influence revenue, including macro conditions such as consumer confidence and spending trends, tariffs and other policies related to drug pricing, economic climate, and our ongoing business development efforts driving our strategic initiatives. It's hard to predict the impact that these variables will ultimately have on our full year revenue, but in an effort to be as transparent as possible, at this point in the year we have greater conviction and visibility at the lower half of our range with achievement of strategic initiatives providing opportunities to deliver in the upper half of our range. With respect to our guidance for full year Adjusted EBITDA3, we are slightly increasing and narrowing the range, now believing it will be between $273 and $287 million, which represents approximately 5% to 10% growth compared to 2024."

    "With the full year guidance as context, for the second quarter, we expect revenue to be up sequentially from the $203 million we reported in the first quarter with an Adjusted EBITDA Margin3 roughly similar to the first quarter," concluded McGinnis.

    3

    Adjusted EBITDA Margin is Adjusted EBITDA divided by Adjusted Revenue. Adjusted EBITDA and Adjusted EBITDA Margin are non-GAAP financial measures and are presented for supplemental informational purposes only. We have not reconciled our Adjusted EBITDA and Adjusted EBITDA Margin guidance to GAAP net income or loss and GAAP net income or loss margin, respectively, because we do not provide guidance for such GAAP measures due to the uncertainty and potential variability of stock-based compensation expense, acquired intangible assets and related amortization and income taxes, which are reconciling items between Adjusted EBITDA and Adjusted EBITDA Margin and their respective most directly comparable GAAP measures. Because such items cannot be provided without unreasonable efforts, we are unable to provide a reconciliation of the non-GAAP financial measure guidance to the corresponding GAAP measure. However, such items could have a significant impact on our future GAAP net income or loss and GAAP net income or loss margin.

    Investor Conference Call and Webcast

    GoodRx management will host a conference call and webcast tomorrow, May 8, 2025, at 5:00 a.m. Pacific Time (8:00 a.m. Eastern Time) to discuss the results and the Company's business outlook.

    To access the conference call, please pre-register using the following link:

    https://register-conf.media-server.com/register/BI7c87cfc603d548b091271cdf679908ed

    Registrants will receive a confirmation with dial-in details and a unique passcode required to join.

    The call will also be webcast live on the Company's investor relations website at https://investors.goodrx.com, where accompanying materials will be posted prior to the conference call.

    Approximately one hour after completion of the live call, an archived version of the webcast will be available on the Company's investor relations website at https://investors.goodrx.com for at least 30 days.

    About GoodRx

    GoodRx is the leading platform for medication savings in the U.S., used by nearly 30 million consumers and over one million healthcare professionals annually. Uniquely situated at the center of the healthcare ecosystem, GoodRx connects consumers, healthcare professionals, payers, pharmacy benefit managers, pharmaceutical manufacturers, and retail pharmacies to make saving on medications easier. By reducing friction and inefficiencies, GoodRx helps consumers save time and money when filling prescriptions so they can get the care they deserve. Since 2011, GoodRx has helped Americans save over $85 billion on the cost of their medications.

    GoodRx periodically posts information that may be important to investors on its investor relations website at https://investors.goodrx.com. We intend to use our website as a means of disclosing material non-public information and for complying with our disclosure obligations under Regulation FD. Accordingly, investors and potential investors are encouraged to consult GoodRx's website regularly for important information, in addition to following GoodRx's press releases, filings with the Securities and Exchange Commission and public conference calls and webcasts. The information contained on, or that may be accessed through, GoodRx's website is not incorporated by reference into, and is not a part of, this press release.

    Forward-Looking Statements

    This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including without limitation statements regarding our future results of operations and financial position, industry and business trends, including uncertainty in the macro environment, the impact on prescription medication price increases on our Monthly Active Consumers, our value proposition, consumer and partner perception and our position in the healthcare ecosystem/industry, our integrated savings programs, our business strategy and our ability to execute on our strategic priorities and value creation, our plans, market opportunity and long-term growth prospects, our capital allocation priorities, our executive officer transitions, our ability to expand our offerings through partnerships with pharmaceutical companies. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including, but not limited to, risks related to our limited operating history and early stage of growth; our recent growth rates may not be sustainable or indicative of future growth; our ability to achieve broad market education and change consumer purchasing habits; our general ability to continue to attract, acquire and retain consumers in a cost-effective manner; our significant reliance on our prescription transactions offering and ability to expand our offerings; changes in medication pricing and the significant impact of pricing structures negotiated by industry participants; our general inability to control the categories and types of prescriptions for which we can offer savings or discounted prices; our reliance on a limited number of industry participants, including pharmacy benefit managers, pharmacies, and pharma manufacturers; the competitive nature of industry; risks related to pandemics, epidemics or outbreak of infectious disease; the accuracy of our estimate of our addressable market and other operational metrics; our ability to respond to changes in the market for prescription pricing and to maintain and expand the use of GoodRx codes; our ability to maintain positive perception of our platform or maintain and enhance our brand; risks related to any failure to maintain effective internal control over financial reporting; risks related to use of social media, emails, text messages and other messaging channels as part of our marketing strategy; our dependence on our information technology systems and those of our third-party vendors, and risks related to any failure or significant disruptions thereof; risks related to government regulation of the internet, e-commerce, consumer data and privacy, information technology and cybersecurity; risks related to the use of AI and machine learning in our business; risks related to a decrease in consumer willingness to receive correspondence or any technical, legal or any other restrictions to send such correspondence; risks related to any failure to comply with applicable data protection, privacy and security, advertising and consumer protection laws, regulations, standards, and other requirements; our ability to utilize our net operating loss carryforwards and certain other tax attributes; the risk that we may be unable to realize expected benefits from our restructuring and cost reduction efforts; our ability to attract, develop, motivate and retain well-qualified employees; risks related to our acquisition strategy; risks related to our debt arrangements; interruptions or delays in service on our apps or websites or any undetected errors or design faults; our reliance on third-party platforms to distribute our platform and offerings, including software as-a-service technologies; systems failures or other disruptions in the operations of these parties on which we depend; risks related to climate change; the increasing focus on environmental sustainability and social initiatives; risks related to our intellectual property; risks related to operating in the healthcare industry; risks related to our organizational structure; litigation related risks; our ability to accurately forecast revenue and appropriately plan our expenses in the future; risks related to general economic factors, natural disasters or other unexpected events; risks related to fluctuations in our tax obligations and effective income tax rate which could materially and adversely affect our results of operations; risks related to the healthcare reform legislation and other proposed or future changes impacting the healthcare industry and healthcare spending which may adversely affect our business, financial condition and results of operations; as well as the other important factors discussed in the section entitled "Risk Factors" of our Annual Report on Form 10-K for the fiscal year ended December 31, 2024, as updated by our Quarterly Report on Form 10-Q for the three months ended March 31, 2025, and in our other filings with the Securities and Exchange Commission. The forward-looking statements in this press release are based upon information available to us as of the date of this press release, and while we believe such information forms a reasonable basis for such statements, such information may be limited or incomplete, and our statements should not be read to indicate that we have conducted an exhaustive inquiry into, or review of, all potentially available relevant information. These statements are inherently uncertain and investors are cautioned not to unduly rely upon these statements. While we may elect to update such forward-looking statements at some point in the future, we disclaim any obligation to do so, even if subsequent events cause our views to change.

    Key Operating Metrics

    Monthly Active Consumers (MACs) refers to the number of unique consumers who have used a GoodRx code to purchase a prescription medication in a given calendar month and have saved money compared to the list price of the medication. A unique consumer who uses a GoodRx code more than once in a calendar month to purchase prescription medications is only counted as one Monthly Active Consumer in that month. A unique consumer who uses a GoodRx code in two or three calendar months within a quarter will be counted as a Monthly Active Consumer in each such month. Monthly Active Consumers do not include subscribers to our subscription offerings, consumers of our pharma manufacturer solutions offering, or consumers who use our telehealth offering. When presented for a period longer than a month, Monthly Active Consumers are averaged over the number of calendar months in such period. Monthly Active Consumers from acquired companies are only included beginning in the first full quarter following the acquisition. Effective January 1, 2025, Monthly Active Consumers from acquired companies are included beginning from the acquisition date. Prior to January 1, 2025, Monthly Active Consumers from acquired companies were only included beginning in the first full quarter following the acquisition.

    Subscription plans represent the ending subscription plan balance across both of our subscription offerings, GoodRx Gold and Kroger Savings Club, the latter of which sunset in July 2024. Each subscription plan may represent more than one subscriber since family subscription plans may include multiple members.

    We exited the first quarter of 2025 with over 7 million prescription-related consumers that used GoodRx across our prescription transactions and subscription offerings. Our prescription-related consumers represent the sum of Monthly Active Consumers for the three months ended March 31, 2025 and subscribers to our subscription plans as of March 31, 2025.

     

    Three Months Ended

    (in millions)

    March 31,

    2025

     

    December 31,

    2024

     

    September 30,

    2024

     

    June 30,

    2024

     

    March 31,

    2024

    Monthly Active Consumers

    6.4

     

    6.6

     

    6.5

     

    6.6

     

    6.7

     

    As of

    (in thousands)

    March 31,

    2025

     

    December 31,

    2024

     

    September 30,

    2024

     

    June 30,

    2024

     

    March 31,

    2024

    Subscription plans

    680

     

    684

     

    701

     

    696

     

    778

    GoodRx Holdings, Inc.

    Condensed Consolidated Balance Sheets (Unaudited)

     

     

    (in thousands, except par values)

     

    March 31, 2025

     

    December 31, 2024

    Assets

     

     

     

    Current assets

     

     

     

    Cash and cash equivalents

    $

    300,981

     

     

    $

    448,346

     

    Accounts receivable, net

     

    160,117

     

     

     

    145,934

     

    Prepaid expenses and other current assets

     

    79,110

     

     

     

    64,975

     

    Total current assets

     

    540,208

     

     

     

    659,255

     

    Property and equipment, net

     

    11,512

     

     

     

    12,664

     

    Goodwill

     

    421,719

     

     

     

    410,769

     

    Intangible assets, net

     

    68,359

     

     

     

    52,102

     

    Capitalized software, net

     

    130,576

     

     

     

    124,781

     

    Operating lease right-of-use assets, net

     

    22,898

     

     

     

    27,794

     

    Deferred tax assets, net

     

    77,182

     

     

     

    77,182

     

    Other assets

     

    22,817

     

     

     

    23,520

     

    Total assets

    $

    1,295,271

     

     

    $

    1,388,067

     

    Liabilities and stockholders' equity

     

     

     

    Current liabilities

     

     

     

    Accounts payable

    $

    15,258

     

     

    $

    14,137

     

    Accrued expenses and other current liabilities

     

    77,567

     

     

     

    99,130

     

    Current portion of debt

     

    5,000

     

     

     

    5,000

     

    Operating lease liabilities, current

     

    5,558

     

     

     

    5,636

     

    Total current liabilities

     

    103,383

     

     

     

    123,903

     

    Debt, net

     

    485,837

     

     

     

    486,711

     

    Operating lease liabilities, net of current portion

     

    44,794

     

     

     

    46,040

     

    Other liabilities

     

    6,910

     

     

     

    6,755

     

    Total liabilities

     

    640,924

     

     

     

    663,409

     

    Stockholders' equity

     

     

     

    Preferred stock, $0.0001 par value

     

    —

     

     

     

    —

     

    Common stock, $0.0001 par value

     

    36

     

     

     

    38

     

    Additional paid-in capital

     

    2,084,272

     

     

     

    2,165,633

     

    Accumulated deficit

     

    (1,429,961

    )

     

     

    (1,441,013

    )

    Total stockholders' equity

     

    654,347

     

     

     

    724,658

     

    Total liabilities and stockholders' equity

    $

    1,295,271

     

     

    $

    1,388,067

     

    GoodRx Holdings, Inc.

    Condensed Consolidated Statements of Operations (Unaudited)

     

     

    (in thousands, except per share amounts)

     

    Three Months Ended March 31,

     

    2025

     

    2024

    Revenue

    $

    202,970

     

     

    $

    197,880

     

    Costs and operating expenses:

     

     

     

    Cost of revenue, exclusive of depreciation and amortization presented separately below

     

    13,364

     

     

     

    12,468

     

    Product development and technology

     

    31,142

     

     

     

    31,017

     

    Sales and marketing

     

    84,542

     

     

     

    89,964

     

    General and administrative

     

    29,630

     

     

     

    41,108

     

    Depreciation and amortization

     

    20,912

     

     

     

    15,942

     

    Total costs and operating expenses

     

    179,590

     

     

     

    190,499

     

    Operating income

     

    23,380

     

     

     

    7,381

     

    Other expense, net:

     

     

     

    Interest income

     

    3,932

     

     

     

    7,555

     

    Interest expense

     

    (10,644

    )

     

     

    (14,643

    )

    Total other expense, net

     

    (6,712

    )

     

     

    (7,088

    )

    Income before income taxes

     

    16,668

     

     

     

    293

     

    Income tax expense

     

    (5,616

    )

     

     

    (1,302

    )

    Net income (loss)

    $

    11,052

     

     

    $

    (1,009

    )

    Earnings (loss) per share:

     

     

     

    Basic

    $

    0.03

     

     

    $

    (0.00

    )

    Diluted

    $

    0.03

     

     

    $

    (0.00

    )

    Weighted average shares used in computing earnings (loss) per share:

     

     

     

    Basic

     

    379,196

     

     

     

    390,048

     

    Diluted

     

    379,656

     

     

     

    390,048

     

     

     

     

     

    Stock-based compensation included in costs and operating expenses:

     

     

     

    Cost of revenue

    $

    100

     

     

    $

    76

     

    Product development and technology

     

    5,670

     

     

     

    5,848

     

    Sales and marketing

     

    5,882

     

     

     

    8,127

     

    General and administrative

     

    7,522

     

     

     

    11,045

     

    GoodRx Holdings, Inc.

    Condensed Consolidated Statements of Cash Flows (Unaudited)

     

     

    (in thousands)

     

    Three Months Ended March 31,

     

    2025

     

    2024

    Cash flows from operating activities

     

     

     

    Net income (loss)

    $

    11,052

     

     

    $

    (1,009

    )

    Adjustments to reconcile net income (loss) to net cash provided by operating activities:

     

     

     

    Depreciation and amortization

     

    20,912

     

     

     

    15,942

     

    Amortization of debt issuance costs and discounts

     

    430

     

     

     

    837

     

    Non-cash operating lease expense

     

    1,086

     

     

     

    895

     

    Stock-based compensation expense

     

    19,174

     

     

     

    25,096

     

    Loss on operating lease asset

     

    4,409

     

     

     

    —

     

    Other

     

    286

     

     

     

    —

     

    Changes in operating assets and liabilities:

     

     

     

    Accounts receivable

     

    (14,183

    )

     

     

    (1,161

    )

    Prepaid expenses and other assets

     

    (13,487

    )

     

     

    3,339

     

    Accounts payable

     

    286

     

     

     

    (2,452

    )

    Accrued expenses and other current liabilities

     

    (19,079

    )

     

     

    924

     

    Operating lease liabilities

     

    (1,628

    )

     

     

    (4

    )

    Other liabilities

     

    155

     

     

     

    179

     

    Net cash provided by operating activities

     

    9,413

     

     

     

    42,586

     

    Cash flows from investing activities

     

     

     

    Purchase of property and equipment

     

    (142

    )

     

     

    (407

    )

    Acquisition

     

    (30,000

    )

     

     

    —

     

    Capitalized software

     

    (21,734

    )

     

     

    (20,208

    )

    Net cash used in investing activities

     

    (51,876

    )

     

     

    (20,615

    )

    Cash flows from financing activities

     

     

     

    Payments on long-term debt

     

    (1,250

    )

     

     

    (3,516

    )

    Repurchases of Class A common stock

     

    (99,897

    )

     

     

    (153,226

    )

    Proceeds from exercise of stock options

     

    2

     

     

     

    2,584

     

    Employee taxes paid related to net share settlement of equity awards

     

    (3,757

    )

     

     

    (6,814

    )

    Net cash used in financing activities

     

    (104,902

    )

     

     

    (160,972

    )

    Net change in cash and cash equivalents

     

    (147,365

    )

     

     

    (139,001

    )

    Cash and cash equivalents

     

     

     

    Beginning of period

     

    448,346

     

     

     

    672,296

     

    End of period

    $

    300,981

     

     

    $

    533,295

     

    For the first quarters of 2025 and 2024, revenue comprised of the following:

     

    (in thousands)

     

    Three Months Ended March 31,

     

    2025

     

    2024

    Prescription transactions revenue

    $

    148,923

     

    $

    145,395

    Subscription revenue

     

    21,017

     

     

     

    22,601

     

    Pharma manufacturer solutions revenue

     

    28,648

     

     

     

    24,509

     

    Other revenue

     

    4,382

     

     

     

    5,375

     

    Total revenue

    $

    202,970

     

     

    $

    197,880

     

    Non-GAAP Financial Measures

    Adjusted Revenue and metrics presented as a percentage of Adjusted Revenue, Adjusted EBITDA, Adjusted EBITDA Margin, Adjusted Net Income, Adjusted Net Income Margin and Adjusted Earnings Per Share are supplemental measures of our performance that are not required by, or presented in accordance with, U.S. GAAP. We also present each cost and operating expense on our condensed consolidated statements of operations on an adjusted basis to arrive at adjusted operating income. Collectively, we refer to these non-GAAP financial measures as our "Non-GAAP Measures."

    We define Adjusted Revenue for a particular period as revenue excluding client contract termination costs associated with restructuring related activities. We exclude these costs from revenue because we believe they are not indicative of past or future underlying performance of the business. For the current period and full year of 2024, revenue was equal to Adjusted Revenue. In addition, we expect revenue for the full year of 2025 to equal Adjusted Revenue.

    We define Adjusted EBITDA for a particular period as net income or loss before interest, taxes, depreciation and amortization, and as further adjusted for, as applicable for the periods presented, acquisition related expenses, stock-based compensation expense, payroll tax expense related to stock-based compensation, loss on extinguishment of debt, financing related expenses, loss on operating lease assets, restructuring related expenses, legal settlement expenses, gain on sale of business, and other income or expense, net. Adjusted EBITDA Margin represents Adjusted EBITDA as a percentage of Adjusted Revenue.

    We define Adjusted Net Income for a particular period as net income or loss adjusted for, as applicable for the periods presented, amortization of intangibles related to acquisitions and restructuring activities, acquisition related expenses, stock-based compensation expense, payroll tax expense related to stock-based compensation, loss on extinguishment of debt, financing related expenses, loss on operating lease assets, restructuring related expenses, legal settlement expenses, gain on sale of business, other expense, and as further adjusted for estimated income tax on such adjusted items. Our adjusted taxes also excludes (i) the valuation allowance recorded against certain of our net deferred tax assets that was recognized in accordance with GAAP and any subsequent releases of the valuation allowance, and (ii) all tax benefits/expenses resulting from excess tax benefits/deficiencies in connection with stock-based compensation. Adjusted Net Income Margin represents Adjusted Net Income as a percentage of Adjusted Revenue.

    Adjusted Earnings Per Share is Adjusted Net Income attributable to common stockholders divided by weighted average number of shares. The weighted average shares we use in computing Adjusted Earnings Per Share – basic is equal to our GAAP weighted average shares – basic and the weighted average shares we use in computing Adjusted Earnings Per Share – diluted is equal to either GAAP weighted average shares – basic or GAAP weighted average shares – diluted, depending on whether we have adjusted net loss or adjusted net income, respectively.

    We also assess our performance by evaluating each cost and operating expense on our condensed consolidated statements of operations on a non-GAAP, or adjusted, basis to arrive at adjusted operating income. The adjustments to these cost and operating expense items include, as applicable for the periods presented, acquisition related expenses, amortization of intangibles related to acquisitions and restructuring activities, stock-based compensation expense, payroll tax expense related to stock-based compensation, financing related expenses, restructuring related expenses, legal settlement expenses, loss on operating lease assets, and gain on sale of business. Adjusted operating income is Adjusted Revenue less non-GAAP costs and operating expenses.

    We believe our Non-GAAP Measures are helpful to investors, analysts and other interested parties because they assist in providing a more consistent and comparable overview of our operations across our historical financial periods. Adjusted Revenue, Adjusted EBITDA and Adjusted EBITDA Margin are also key measures we use to assess our financial performance and are also used for internal planning and forecasting purposes. In addition, Adjusted Revenue, Adjusted EBITDA, Adjusted EBITDA Margin, Adjusted Net Income and Adjusted Earnings Per Share are frequently used by analysts, investors and other interested parties to evaluate and assess performance.

    The Non-GAAP Measures are presented for supplemental informational purposes only and should not be considered as alternatives or substitutes to financial information presented in accordance with GAAP. These measures have certain limitations in that they do not include the impact of certain costs that are reflected in our condensed consolidated statements of operations that are necessary to run our business. Other companies, including other companies in our industry, may not use these measures or may calculate these measures differently than as presented herein, limiting their usefulness as comparative measures.

    The following table presents a reconciliation of net income (loss), the most directly comparable financial measure calculated in accordance with GAAP, to Adjusted EBITDA, and presents net income (loss) margin, the most directly comparable financial measure calculated in accordance with GAAP, with Adjusted EBITDA Margin:

    (dollars in thousands)

     

    Three Months Ended

    March 31,

     

    Three Months Ended

    December 31,

     

    Year Ended

    December 31,

     

    2025

     

    2024

     

    2024

     

    2024

    Net income (loss)

    $

    11,052

     

     

    $

    (1,009

    )

     

    $

    6,740

     

     

    $

    16,390

     

    Adjusted to exclude the following:

     

     

     

     

     

     

     

    Interest income

     

    (3,932

    )

     

     

    (7,555

    )

     

     

    (4,587

    )

     

     

    (23,273

    )

    Interest expense

     

    10,644

     

     

     

    14,643

     

     

     

    11,358

     

     

     

    52,922

     

    Income tax expense

     

    5,616

     

     

     

    1,302

     

     

     

    4,669

     

     

     

    15,070

     

    Depreciation and amortization

     

    20,912

     

     

     

    15,942

     

     

     

    19,096

     

     

     

    69,538

     

    Other expense

     

    —

     

     

     

    —

     

     

     

    —

     

     

     

    2,660

     

    Loss on extinguishment of debt

     

    —

     

     

     

    —

     

     

     

    —

     

     

     

    2,077

     

    Financing related expenses

     

    —

     

     

     

    440

     

     

     

    —

     

     

     

    898

     

    Acquisition related expenses

     

    26

     

     

     

    174

     

     

     

    144

     

     

     

    557

     

    Restructuring related expenses

     

    1,219

     

     

     

    (125

    )

     

     

    8,461

     

     

     

    8,902

     

    Legal settlement expenses

     

    —

     

     

     

    13,000

     

     

     

    —

     

     

     

    13,000

     

    Stock-based compensation expense

     

    19,174

     

     

     

    25,096

     

     

     

    20,959

     

     

     

    99,026

     

    Payroll tax expense related to stock-based compensation

     

    685

     

     

     

    879

     

     

     

    235

     

     

     

    2,471

     

    Loss on operating lease asset

     

    4,409

     

     

     

    —

     

     

     

    —

     

     

     

    —

     

    Adjusted EBITDA

    $

    69,805

     

     

    $

    62,787

     

     

    $

    67,075

     

     

    $

    260,238

     

     

     

     

     

     

     

     

     

    Revenue

    $

    202,970

     

     

    $

    197,880

     

     

    $

    198,583

     

     

    $

    792,324

     

    Net income (loss) margin

     

    5.4

    %

     

     

    (0.5

    %)

     

     

    3.4

    %

     

     

    2.1

    %

    Adjusted EBITDA Margin

     

    34.4

    %

     

     

    31.7

    %

     

     

    33.8

    %

     

     

    32.8

    %

    The following tables present a reconciliation of net income (loss) and calculations of net income (loss) margin and earnings (loss) per share, the most directly comparable financial measures calculated in accordance with GAAP, to Adjusted Net Income, Adjusted Net Income Margin, and Adjusted Earnings Per Share, respectively:

    (dollars in thousands, except per share amounts)

     

    Three Months Ended March 31,

     

    2025

     

    2024

    Net income (loss)

    $

    11,052

     

     

    $

    (1,009

    )

    Adjusted to exclude the following:

     

     

     

    Amortization of intangibles related to acquisitions

     

    2,793

     

     

     

    2,776

     

    Financing related expenses

     

    —

     

     

     

    440

     

    Acquisition related expenses

     

    26

     

     

     

    174

     

    Restructuring related expenses

     

    1,219

     

     

     

    (125

    )

    Legal settlement expenses

     

    —

     

     

     

    13,000

     

    Stock-based compensation expense

     

    19,174

     

     

     

    25,096

     

    Payroll tax expense related to stock-based compensation

     

    685

     

     

     

    879

     

    Loss on operating lease asset

     

    4,409

     

     

     

    —

     

    Income tax effects of excluded items and adjustments for valuation allowance and excess tax benefits/deficiencies from equity awards

     

    (4,995

    )

     

     

    (8,645

    )

    Adjusted Net Income

    $

    34,363

     

     

    $

    32,586

     

     

     

     

     

    Revenue

    $

    202,970

     

     

    $

    197,880

     

    Net income (loss) margin

     

    5.4

    %

     

     

    (0.5

    %)

    Adjusted Net Income Margin

     

    16.9

    %

     

     

    16.5

    %

    Weighted average shares used in computing earnings (loss) per share:

     

     

     

    Basic

     

    379,196

     

     

     

    390,048

     

    Diluted

     

    379,656

     

     

     

    390,048

     

    Earnings (loss) per share:

     

     

     

    Basic

    $

    0.03

     

     

    $

    (0.00

    )

    Diluted

    $

    0.03

     

     

    $

    (0.00

    )

    Weighted average shares used in computing Adjusted Earnings Per Share:

     

     

     

    Basic

     

    379,196

     

     

     

    390,048

     

    Diluted

     

    379,656

     

     

     

    396,505

     

    Adjusted Earnings Per Share:

     

     

     

    Basic

    $

    0.09

     

     

    $

    0.08

     

    Diluted

    $

    0.09

     

     

    $

    0.08

     

    The following table presents (i) each non-GAAP, or adjusted, cost and expense and operating income measure together with its most directly comparable financial measure calculated in accordance with GAAP; and (ii) each adjusted cost and expense and adjusted operating income as a percentage of Adjusted Revenue together with each GAAP cost and expense and operating income as a percentage of revenue, the most directly comparable financial measure calculated in accordance with GAAP:

    (dollars in thousands)

     

    GAAP

     

    Adjusted

     

    Three Months Ended

    March 31,

     

    Three Months Ended

    March 31,

     

    2025

     

    2024

     

    2025

     

    2024

    Cost of revenue

    $13,364

     

    $12,468

     

    $13,258

     

    $12,696

    % of Revenue

    7%

     

    6%

     

    7%

     

    6%

    Product development and technology

    $31,142

     

    $31,017

     

    $23,990

     

    $24,578

    % of Revenue

    15%

     

    16%

     

    12%

     

    12%

    Sales and marketing

    $84,542

     

    $89,964

     

    $78,404

     

    $81,396

    % of Revenue

    42%

     

    45%

     

    39%

     

    41%

    General and administrative

    $29,630

     

    $41,108

     

    $17,513

     

    $16,423

    % of Revenue

    15%

     

    21%

     

    9%

     

    8%

    Depreciation and amortization

    $20,912

     

    $15,942

     

    $18,119

     

    $13,166

    % of Revenue

    10%

     

    8%

     

    9%

     

    7%

    Operating income

    $23,380

     

    $7,381

     

    $51,686

     

    $49,621

    % of Revenue

    12%

     

    4%

     

    25%

     

    25%

    The following table presents a reconciliation of each non-GAAP, or adjusted, cost and expense and operating income measure to its most directly comparable financial measure calculated in accordance with GAAP:

     

    (dollars in thousands)

     

    Three Months Ended March 31,

     

    2025

     

    2024

    Cost of revenue

    $

    13,364

     

     

    $

    12,468

     

    Restructuring related expenses

     

    (2

    )

     

     

    311

     

    Stock-based compensation expense

     

    (100

    )

     

     

    (76

    )

    Payroll tax expense related to stock-based compensation

     

    (4

    )

     

     

    (7

    )

    Adjusted cost of revenue

    $

    13,258

     

     

    $

    12,696

     

     

     

     

     

    Product development and technology

    $

    31,142

     

     

    $

    31,017

     

    Acquisition related expenses

     

    —

     

     

     

    (26

    )

    Restructuring related expenses

     

    (1,109

    )

     

     

    (92

    )

    Stock-based compensation expense

     

    (5,670

    )

     

     

    (5,848

    )

    Payroll tax expense related to stock-based compensation

     

    (373

    )

     

     

    (473

    )

    Adjusted product development and technology

    $

    23,990

     

     

    $

    24,578

     

     

     

     

     

    Sales and marketing

    $

    84,542

     

     

    $

    89,964

     

    Acquisition related expenses

     

    —

     

     

     

    (148

    )

    Restructuring related expenses

     

    (87

    )

     

     

    (114

    )

    Stock-based compensation expense

     

    (5,882

    )

     

     

    (8,127

    )

    Payroll tax expense related to stock-based compensation

     

    (169

    )

     

     

    (179

    )

    Adjusted sales and marketing

    $

    78,404

     

     

    $

    81,396

     

     

     

     

     

    General and administrative

    $

    29,630

     

     

    $

    41,108

     

    Financing related expenses

     

    —

     

     

     

    (440

    )

    Acquisition related expenses

     

    (26

    )

     

     

    —

     

    Restructuring related expenses

     

    (21

    )

     

     

    20

     

    Legal settlement expenses

     

    —

     

     

     

    (13,000

    )

    Stock-based compensation expense

     

    (7,522

    )

     

     

    (11,045

    )

    Payroll tax expense related to stock-based compensation

     

    (139

    )

     

     

    (220

    )

    Loss on operating lease asset

     

    (4,409

    )

     

     

    —

     

    Adjusted general and administrative

    $

    17,513

     

     

    $

    16,423

     

     

     

     

     

    Depreciation and amortization

    $

    20,912

     

     

    $

    15,942

     

    Amortization of intangibles related to acquisitions

     

    (2,793

    )

     

     

    (2,776

    )

    Adjusted depreciation and amortization

    $

    18,119

     

     

    $

    13,166

     

     

     

     

     

    Operating income

    $

    23,380

     

     

    $

    7,381

     

    Amortization of intangibles related to acquisitions

     

    2,793

     

     

     

    2,776

     

    Financing related expenses

     

    —

     

     

     

    440

     

    Acquisition related expenses

     

    26

     

     

     

    174

     

    Restructuring related expenses

     

    1,219

     

     

     

    (125

    )

    Legal settlement expenses

     

    —

     

     

     

    13,000

     

    Stock-based compensation expense

     

    19,174

     

     

     

    25,096

     

    Payroll tax expense related to stock-based compensation

     

    685

     

     

     

    879

     

    Loss on operating lease asset

     

    4,409

     

     

     

    —

     

    Adjusted operating income

    $

    51,686

     

     

    $

    49,621

     

     

    View source version on businesswire.com: https://www.businesswire.com/news/home/20250507409770/en/

    Investor Contact

    GoodRx

    Aubrey Reynolds

    [email protected]

    Press Contact

    GoodRx

    Lauren Casparis

    [email protected]

    Get the next $GDRX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $GDRX

    DatePrice TargetRatingAnalyst
    12/4/2024$5.00Neutral
    Mizuho
    8/9/2024$10.00Outperform → Strong Buy
    Raymond James
    5/23/2024$8.00 → $10.00Sector Perform → Outperform
    RBC Capital Mkts
    5/16/2024$10.00Mkt Perform → Outperform
    Raymond James
    4/10/2024$9.00Sector Weight → Overweight
    KeyBanc Capital Markets
    3/25/2024$7.50 → $10.00Equal Weight → Overweight
    Wells Fargo
    3/1/2024$7.00 → $10.00Neutral → Overweight
    JP Morgan
    2/26/2024$8.00Outperform
    Leerink Partners
    More analyst ratings

    $GDRX
    Leadership Updates

    Live Leadership Updates

    See more
    • GoodRx Appoints Aaron Crittenden as President of Rx Marketplace and Scott Pope, PharmD, as Chief Pharmacy Officer and Head of Clinical Engagement

      Accomplished healthcare executives will work to drive growth, strengthen industry partnerships, and enhance pharmacy innovation at GoodRx GoodRx (NASDAQ:GDRX), the leading platform for medication savings in the U.S., today announced the appointment of Aaron Crittenden as President of Rx Marketplace and Scott Pope, PharmD, as Chief Pharmacy Officer and Head of Clinical Engagement, effective immediately. Aaron will be responsible for the management and financial performance of GoodRx's Rx Marketplace offering, working with key retail pharmacy, pharmacy benefit manager (PBM), employer, and manufacturer partners. He will also play a critical role in shaping GoodRx's long-term growth strategy

      3/17/25 9:00:00 AM ET
      $GDRX
      EDP Services
      Technology
    • GoodRx Appoints Christopher A. McGinnis as Chief Financial Officer

      Seasoned industry executive brings decades of financial strategy and leadership experience to GoodRx GoodRx (NASDAQ:GDRX), the leading prescription savings platform in the U.S., today announced that Christopher A. McGinnis has been appointed as Chief Financial Officer, effective February 4, 2025. Chris brings 30 years of extensive financial experience across the healthcare industry to his new role. Chris will join GoodRx following his role as CEO of CitizensRx, where he led the company in providing pharmacy benefit management services to commercial clients. Before that, Chris held various executive roles at Lumeris / Essence Healthcare, a Medicare Advantage plan and value-based healthca

      2/5/25 4:05:00 PM ET
      $GDRX
      EDP Services
      Technology
    • WM Technology, Inc. Names Sarah Griffis Chief Technology Officer

      WM Technology, Inc. ("WM Technology" or the "Company") (NASDAQ:MAPS), a leading marketplace and technology solutions provider to the cannabis industry, today announced the appointment of Sarah Griffis as the Company's new Chief Technology Officer, effective January 6, 2025. "I am thrilled to welcome Sarah as our new CTO. She has great experience not just building and leading engineering and tech teams, but also operating in regulated industries like ours," said Doug Francis, Chief Executive Officer at Weedmaps. "I look forward to partnering with her and the rest of our tech org to continue delivering innovative and best-in-class technology solutions to our customers." Prior to joining W

      1/6/25 9:00:00 AM ET
      $GDRX
      $MAPS
      EDP Services
      Technology
      Computer Software: Prepackaged Software

    $GDRX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Mizuho initiated coverage on GoodRx with a new price target

      Mizuho initiated coverage of GoodRx with a rating of Neutral and set a new price target of $5.00

      12/4/24 7:38:07 AM ET
      $GDRX
      EDP Services
      Technology
    • GoodRx upgraded by Raymond James with a new price target

      Raymond James upgraded GoodRx from Outperform to Strong Buy and set a new price target of $10.00

      8/9/24 7:30:17 AM ET
      $GDRX
      EDP Services
      Technology
    • GoodRx upgraded by RBC Capital Mkts with a new price target

      RBC Capital Mkts upgraded GoodRx from Sector Perform to Outperform and set a new price target of $10.00 from $8.00 previously

      5/23/24 7:39:11 AM ET
      $GDRX
      EDP Services
      Technology

    $GDRX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • GoodRx to Launch Direct Contracting for Independent Community Pharmacies

      GoodRx is hosting a webinar on June 3 and 4 to discuss how the company is supporting direct contracting with GoodRx GoodRx (NASDAQ:GDRX), the leading platform for medication savings in the U.S., today announced that it will launch a new offering for independent community pharmacies - GoodRx Community Link - in June 2025. GoodRx Community Link will enable locally owned and operated pharmacies to directly contract with GoodRx on pricing and manage participation in the company's Integrated Savings Programs (ISP). Direct contracts leverage cost-plus models to provide independent pharmacies with more direct control over pricing and favorable margins. GoodRx is committed to helping independent

      5/22/25 9:00:00 AM ET
      $GDRX
      EDP Services
      Technology
    • GoodRx Reports First Quarter 2025 Results

      First Quarter 2025 Revenue In-line; Adjusted EBITDA Margin Beats Previous Guidance; Maintains Full Year 2025 Revenue Guidance Range; Raises Adjusted EBITDA Expectations GoodRx Holdings, Inc. (NASDAQ:GDRX) ("we," "us," "our," "GoodRx," or the "Company"), the leading platform for medication savings in the U.S., has released its financial results for the first quarter of 2025. First Quarter 2025 Highlights Revenue of $203.0 million Net income of $11.1 million; Net income margin of 5.4% Adjusted Net Income1 of $34.4 million; Adjusted Net Income Margin1 of 16.9% Adjusted EBITDA1 of $69.8 million; Adjusted EBITDA Margin1 of 34.4% Net cash provided by operating activities of $9.4 milli

      5/7/25 4:13:00 PM ET
      $GDRX
      EDP Services
      Technology
    • GoodRx Announces Date for First Quarter 2025 Earnings Release and Conference Call

      GoodRx Holdings, Inc. (NASDAQ:GDRX) ("GoodRx" or the "Company"), the leading platform for medication savings in the U.S., today announced it will release its first quarter 2025 financial results after U.S. markets close on Wednesday, May 7, 2025. GoodRx management will also hold a conference call and webcast the following morning, Thursday, May 8, 2025 at 5:00 a.m. Pacific Time (8:00 a.m. Eastern Time) to discuss the results and the Company's business outlook. To access the conference call, please pre-register using this link. Registrants will receive a confirmation with dial-in details and a unique passcode required to join. The call will also be webcast live on the Company's investor rel

      4/9/25 4:05:00 PM ET
      $GDRX
      EDP Services
      Technology

    $GDRX
    SEC Filings

    See more
    • Amendment: SEC Form SCHEDULE 13G/A filed by GoodRx Holdings Inc.

      SCHEDULE 13G/A - GoodRx Holdings, Inc. (0001809519) (Subject)

      5/15/25 10:57:58 AM ET
      $GDRX
      EDP Services
      Technology
    • Amendment: SEC Form SCHEDULE 13G/A filed by GoodRx Holdings Inc.

      SCHEDULE 13G/A - GoodRx Holdings, Inc. (0001809519) (Subject)

      5/14/25 4:04:49 PM ET
      $GDRX
      EDP Services
      Technology
    • SEC Form 10-Q filed by GoodRx Holdings Inc.

      10-Q - GoodRx Holdings, Inc. (0001809519) (Filer)

      5/7/25 4:50:11 PM ET
      $GDRX
      EDP Services
      Technology

    $GDRX
    Financials

    Live finance-specific insights

    See more

    $GDRX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more

    $GDRX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • GoodRx Reports First Quarter 2025 Results

      First Quarter 2025 Revenue In-line; Adjusted EBITDA Margin Beats Previous Guidance; Maintains Full Year 2025 Revenue Guidance Range; Raises Adjusted EBITDA Expectations GoodRx Holdings, Inc. (NASDAQ:GDRX) ("we," "us," "our," "GoodRx," or the "Company"), the leading platform for medication savings in the U.S., has released its financial results for the first quarter of 2025. First Quarter 2025 Highlights Revenue of $203.0 million Net income of $11.1 million; Net income margin of 5.4% Adjusted Net Income1 of $34.4 million; Adjusted Net Income Margin1 of 16.9% Adjusted EBITDA1 of $69.8 million; Adjusted EBITDA Margin1 of 34.4% Net cash provided by operating activities of $9.4 milli

      5/7/25 4:13:00 PM ET
      $GDRX
      EDP Services
      Technology
    • GoodRx Announces Date for First Quarter 2025 Earnings Release and Conference Call

      GoodRx Holdings, Inc. (NASDAQ:GDRX) ("GoodRx" or the "Company"), the leading platform for medication savings in the U.S., today announced it will release its first quarter 2025 financial results after U.S. markets close on Wednesday, May 7, 2025. GoodRx management will also hold a conference call and webcast the following morning, Thursday, May 8, 2025 at 5:00 a.m. Pacific Time (8:00 a.m. Eastern Time) to discuss the results and the Company's business outlook. To access the conference call, please pre-register using this link. Registrants will receive a confirmation with dial-in details and a unique passcode required to join. The call will also be webcast live on the Company's investor rel

      4/9/25 4:05:00 PM ET
      $GDRX
      EDP Services
      Technology
    • GoodRx Reports Fourth Quarter and Full Year 2024 Results

      Fourth Quarter and Full Year 2024 Results Substantially In-line with Previous Guidance GoodRx Holdings, Inc. (NASDAQ:GDRX) ("we," "us," "our," "GoodRx," or the "Company"), the leading prescription savings platform in the U.S., has released its financial results for the fourth quarter and full year of 2024. Fourth Quarter 2024 Highlights Revenue1 of $198.6 million Net income of $6.7 million; Net income margin of 3.4% Adjusted Net Income1 of $34.7 million; Adjusted Net Income Margin1 of 17.5% Adjusted EBITDA1 of $67.1 million; Adjusted EBITDA Margin1 of 33.8% Net cash provided by operating activities of $44.7 million Exited the quarter with over 7 million consumers of pr

      2/27/25 6:05:00 AM ET
      $GDRX
      EDP Services
      Technology
    • Chief Accounting Officer Nabiey Romin converted options into 4,804 shares and covered exercise/tax liability with 1,719 shares, increasing direct ownership by 3% to 118,091 units (SEC Form 4)

      4 - GoodRx Holdings, Inc. (0001809519) (Issuer)

      5/15/25 5:46:56 PM ET
      $GDRX
      EDP Services
      Technology
    • Chief Accounting Officer Nabiey Romin converted options into 12,663 shares and covered exercise/tax liability with 4,531 shares, increasing direct ownership by 8% to 115,006 units (SEC Form 4)

      4 - GoodRx Holdings, Inc. (0001809519) (Issuer)

      5/8/25 6:16:12 PM ET
      $GDRX
      EDP Services
      Technology
    • Director Idea Men, Llc converted options into 7,000,000 shares and returned $29,400,000 worth of shares to the company (7,000,000 units at $4.20) (SEC Form 4)

      4 - GoodRx Holdings, Inc. (0001809519) (Issuer)

      3/21/25 4:23:24 PM ET
      $GDRX
      EDP Services
      Technology
    • Wagner Scott bought $124,806 worth of shares (21,652 units at $5.76) (SEC Form 4)

      4 - GoodRx Holdings, Inc. (0001809519) (Issuer)

      12/4/23 4:35:10 PM ET
      $GDRX
      EDP Services
      Technology
    • Wagner Scott bought $180,423 worth of shares (30,505 units at $5.91) (SEC Form 4)

      4 - GoodRx Holdings, Inc. (0001809519) (Issuer)

      11/30/23 4:41:35 PM ET
      $GDRX
      EDP Services
      Technology
    • Wagner Scott bought $677,475 worth of shares (130,743 units at $5.18) (SEC Form 4)

      4 - GoodRx Holdings, Inc. (0001809519) (Issuer)

      11/17/23 7:08:30 PM ET
      $GDRX
      EDP Services
      Technology

    $GDRX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by GoodRx Holdings Inc.

      SC 13G/A - GoodRx Holdings, Inc. (0001809519) (Subject)

      11/14/24 12:29:56 PM ET
      $GDRX
      EDP Services
      Technology
    • Amendment: SEC Form SC 13G/A filed by GoodRx Holdings Inc.

      SC 13G/A - GoodRx Holdings, Inc. (0001809519) (Subject)

      11/13/24 4:30:24 PM ET
      $GDRX
      EDP Services
      Technology
    • Amendment: SEC Form SC 13G/A filed by GoodRx Holdings Inc.

      SC 13G/A - GoodRx Holdings, Inc. (0001809519) (Subject)

      11/12/24 4:02:41 PM ET
      $GDRX
      EDP Services
      Technology